This project focuses on improving treatment and survival for children with some of the most high-risk brain cancers.
Brain cancer accounts for 40 percent of paediatric cancer deaths. There has been no significant improvement in survival rates in decades. High-grade gliomas (HGG) are particularly aggressive and deadly brain tumours.
Genetic mutations alter the activity of proteins controlling the growth and survival of cancer cells. For children diagnosed with HGG, we are yet to understand how these pathways function.
This project, led by Associate Professor Matt Dun, will combine the investigation of tumour genomics and protein architecture to establish patient-specific therapeutic options with the greatest chance of survival.
Associate Professor Matt Dun
The University of Newcastle, Hunter Medical Research Institute
$300,000 October 2021 to September 2024
Associate Proffessor Matt Dun is an NHMRC research fellow from The University of Newcastle in the Shcool of Biomedical Sciences and Pharmacy. He has been supported by TKCP since October of 2021. Assoc. Prof. Dun has personal experience of childhood cancer with his daughter affected. Matt's daughter Josie was diagnosed with deadly brain stem cancer, Diffuse Instrinsic Pontine Glioma (DIPG) at 2 years of age. Josie died 22 months later. This experience saw Dr Dun shift focus from blood cancer to brain cancers where he continues his research efforts to increase understanding regarding the pathophysiology of the disease and improve survivability.
Acute myeloid leukaemia (AML)
A highly fatal blood cancer in adults and children. By adding a newly developed NAMPT inhibitor to standard of care treatment, this project can pave the way towards a more effective treatment of poor outcome adult and paediatric AML.
Paediatric high-grade glioma (HGG)
This project focuses on improving treatment and survival for children with some of the most high-risk brain cancers
Providing access to international clinical trials and additional clinical trial expertise
ANZCHOG international trials set up and manage the clinical trials for bran new kids' cancer treatments, giving kids access to the very latest therapies.
RECOVER – Responding to late effects in survivors of childhood cancer
Empowering young survivors of childhood cancer to transition to adulthood with the knowledge, skills and resources required to manage their ongoing health needs.
Treatment toxicity can cause infertility
Developing genetic risk prediction of long term infertility from childhood cancer therapies leading to informed decisions and application of preventive measures.
Sarcoma (bone & soft tissue cancer)
Clinical translation of laboratory tested CAR T cell therapy into Phase 1 trials for paediatric treatment of sarcoma.
I authorise The Kids' Cancer Project to contact me about
Thank you for making a donation to the campain.
2% will be added to your total cost and continue for any recurring payments.
Pay with PayPal